GLYC News and Press, GlycoMimetics Inc. From 03/02/22

ABUS, ARGX, ASPS, ATRS, BBY, BF.B, BIG, BILI, BJ, BURL, CAN, CNCE, CNQ, CNSL, CPG, CRH, OTCQX:DLAKF, EYPT, GLYC, GOGO, GRAB, HTOO, KR, MBT, MCS, MEI, OTCPK:MKGAF, MTLS, OXSQ, REE, REV, SBSW, OTCPK:SNCAF, SOHO, SRLP, STXS, SUP, TD, TGLS, TTC, TTSH, TWI, TZOO, UONE, UTZ, WB, WHF, WVE For Seekin...

GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Dr. Deepak Tiwari has joined the Company as Vice President, Technical Operations. “Dr. Tiwari brings over 25 years of diverse CMC experience. He has contributed to more than 30 regulatory submissions and 15 commercial pr...

GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its fourth quarter and 2021 year-end financial results on Thursday, March 3, 2022, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic ...

GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Bruce Johnson has joined its executive leadership team as Senior Vice President and Chief Commercial Officer. “Bruce brings to GlycoMimetics a wealth of oncology / hematology expertise particularly in leading commercial ...

Preclinical studies were conducted at the University of Texas MD Anderson Cancer Center Data support novel therapeutic approach for patients with acute myeloid leukemia (AML) with FLT-3 ITD mutations GlycoMimetics, Inc. (Nasdaq: GLYC) this week at the 63 rd A...

Completion of enrollment sets the stage for planned interim analysis evaluating event-free survival and potential for regulatory filings, if positive GlycoMimetics, Inc. (Nasdaq: GLYC), a clinical-stage biotechnology company, announced today that the National Cancer Institut...

GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Apollomics has dosed the first patient in China in a Phase 3 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML). Apollomics’ Phase 3 trial w...

GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Lisa DeLuca, Ph.D., has joined its executive leadership team as Vice President, Regulatory Affairs. Dr. DeLuca is a veteran regulatory expert who has previously led the strategy-formation and execution of multiple global NDA submis...

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced completion of enrollment of its pivotal Phase 3 trial evaluating uproleselan in addition to a standard chemotherapy regimen in patients with relapsed/refractory AML. A total of 388 patients across 70 sites in nine countries has now been...

GlycoMimetics’ main AML trial is close to completion of enrollment. Uproleselan Phase 3 trial likely to build on prior positive data. Results from a National Cancer Institute trial could expand the label. For further details see: GlycoMimetics A Buy On Nearing Tri...